These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 32453047)

  • 1. Repeated Occurrences of Basal Cell Cancer in Patients With Inflammatory Bowel Disease Treated With Immunosuppressive Medications.
    Khan N; Patel D; Trivedi C; Kavani H; Medvedeva E; Pernes T; Xie D; Lewis J; Yang YX
    Am J Gastroenterol; 2020 Aug; 115(8):1246-1252. PubMed ID: 32453047
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risks of Melanoma and Nonmelanoma Skin Cancers Pre- and Post-Inflammatory Bowel Disease Diagnosis.
    Narous M; Nugent Z; Singh H; Bernstein CN
    Inflamm Bowel Dis; 2023 Jul; 29(7):1047-1056. PubMed ID: 35929649
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of Nonmelanoma Skin Cancer Associated With the Use of Immunosuppressant and Biologic Agents in Patients With a History of Autoimmune Disease and Nonmelanoma Skin Cancer.
    Scott FI; Mamtani R; Brensinger CM; Haynes K; Chiesa-Fuxench ZC; Zhang J; Chen L; Xie F; Yun H; Osterman MT; Beukelman T; Margolis DJ; Curtis JR; Lewis JD
    JAMA Dermatol; 2016 Feb; 152(2):164-72. PubMed ID: 26510126
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased risk of nonmelanoma skin cancers among individuals with inflammatory bowel disease.
    Singh H; Nugent Z; Demers AA; Bernstein CN
    Gastroenterology; 2011 Nov; 141(5):1612-20. PubMed ID: 21806945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Severity of Herpes Zoster in Inflammatory Bowel Disease Patients Treated With Anti-TNF Agents.
    Khan N; Trivedi C; Shah Y; Patel D; Lewis J; Yang YX
    Inflamm Bowel Dis; 2018 May; 24(6):1274-1279. PubMed ID: 29522099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overall and Comparative Risk of Herpes Zoster With Pharmacotherapy for Inflammatory Bowel Diseases: A Nationwide Cohort Study.
    Khan N; Patel D; Trivedi C; Shah Y; Lichtenstein G; Lewis J; Yang YX
    Clin Gastroenterol Hepatol; 2018 Dec; 16(12):1919-1927.e3. PubMed ID: 29309905
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of malignancies in patients with inflammatory bowel disease treated with thiopurines or anti-TNF alpha antibodies.
    Beigel F; Steinborn A; Schnitzler F; Tillack C; Breiteneicher S; John JM; Van Steen K; Laubender RP; Göke B; Seiderer J; Brand S; Ochsenkühn T
    Pharmacoepidemiol Drug Saf; 2014 Jul; 23(7):735-44. PubMed ID: 24788825
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mortality Associated With Development of Squamous Cell Cancer in Patients With Inflammatory Bowel Diseases Receiving Treatment With Thiopurines.
    Khan N; Lee H; Trivedi C; Kavani H; Medvedeva E; Xie D; Lewis JD; Yang YX
    Clin Gastroenterol Hepatol; 2019 Oct; 17(11):2262-2268. PubMed ID: 30853615
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence of Acute Myeloid Leukemia and Myelodysplastic Syndrome in Patients With Inflammatory Bowel Disease and the Impact of Thiopurines on Their Risk.
    Khan N; Patel D; Trivedi C; Kavani H; Pernes T; Medvedeva E; Lewis J; Xie D; Yang YX
    Am J Gastroenterol; 2021 Apr; 116(4):741-747. PubMed ID: 33982944
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of thiopurine and anti-TNF therapy in lymphoma in inflammatory bowel disease.
    Herrinton LJ; Liu L; Weng X; Lewis JD; Hutfless S; Allison JE
    Am J Gastroenterol; 2011 Dec; 106(12):2146-53. PubMed ID: 22031357
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of SARS-CoV-2 Vaccination in a Veterans Affairs Cohort of Patients With Inflammatory Bowel Disease With Diverse Exposure to Immunosuppressive Medications.
    Khan N; Mahmud N
    Gastroenterology; 2021 Sep; 161(3):827-836. PubMed ID: 34048782
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Review article: dermatological complications of immunosuppressive and anti-TNF therapy in inflammatory bowel disease.
    Moran GW; Lim AW; Bailey JL; Dubeau MF; Leung Y; Devlin SM; Novak K; Kaplan GG; Iacucci M; Seow C; Martin L; Panaccione R; Ghosh S
    Aliment Pharmacol Ther; 2013 Nov; 38(9):1002-24. PubMed ID: 24099467
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of lymphoma in patients with ulcerative colitis treated with thiopurines: a nationwide retrospective cohort study.
    Khan N; Abbas AM; Lichtenstein GR; Loftus EV; Bazzano LA
    Gastroenterology; 2013 Nov; 145(5):1007-1015.e3. PubMed ID: 23891975
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Level of UV Exposure, Skin Type, and Age Are More Important than Thiopurine Use for Keratinocyte Carcinoma Development in IBD Patients.
    Wu Y; Ghaly S; Kerr S; Jackson B; Hanigan K; Martins D; Krishnaprasad K; Mountifield RE; Whiteman DC; Bampton PA; Gearry RB; Radford-Smith GL; Lawrance IC
    Dig Dis Sci; 2020 Apr; 65(4):1172-1179. PubMed ID: 31493039
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-TNF agents in patients with inflammatory bowel disease and malignant melanoma--challenges in management.
    Lee J; Clarke K
    Int J Colorectal Dis; 2015 Dec; 30(12):1595-602. PubMed ID: 26349591
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatitis B Virus Screening and Reactivation in a National VA Cohort of Patients with Inflammatory Bowel Disease Treated with Tumor Necrosis Factor Antagonists.
    Shah R; Ho EY; Kramer JR; Richardson P; Sansgiry S; El-Serag HB; Hou JK
    Dig Dis Sci; 2018 Jun; 63(6):1551-1557. PubMed ID: 29663266
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased risk for non-melanoma skin cancer in patients with inflammatory bowel disease.
    Long MD; Herfarth HH; Pipkin CA; Porter CQ; Sandler RS; Kappelman MD
    Clin Gastroenterol Hepatol; 2010 Mar; 8(3):268-74. PubMed ID: 20005977
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extra-intestinal malignancies in inflammatory bowel disease: results of the 3rd ECCO Pathogenesis Scientific Workshop (III).
    Magro F; Peyrin-Biroulet L; Sokol H; Aldeger X; Costa A; Higgins PD; Joyce JC; Katsanos KH; Lopez A; de Xaxars TM; Toader E; Beaugerie L
    J Crohns Colitis; 2014 Jan; 8(1):31-44. PubMed ID: 23721759
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of New or Recurrent Cancer in Patients With Inflammatory Bowel Disease and Previous Cancer Exposed to Immunosuppressive and Anti-Tumor Necrosis Factor Agents.
    Axelrad J; Bernheim O; Colombel JF; Malerba S; Ananthakrishnan A; Yajnik V; Hoffman G; Agrawal M; Lukin D; Desai A; McEachern E; Bosworth B; Scherl E; Reyes A; Zaidi H; Mudireddy P; DiCaprio D; Sultan K; Korelitz B; Wang E; Williams R; Chen L; Katz S; Itzkowitz S;
    Clin Gastroenterol Hepatol; 2016 Jan; 14(1):58-64. PubMed ID: 26247164
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease.
    Peyrin-Biroulet L; Khosrotehrani K; Carrat F; Bouvier AM; Chevaux JB; Simon T; Carbonnel F; Colombel JF; Dupas JL; Godeberge P; Hugot JP; Lémann M; Nahon S; Sabaté JM; Tucat G; Beaugerie L;
    Gastroenterology; 2011 Nov; 141(5):1621-28.e1-5. PubMed ID: 21708105
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.